Anuh Pharma Share Price

Anuh Pharma Limited, with its corporate operations in Mumbai, functions as a bulk drug and chemical manufacturer in India . The company was incorporated in 1960 . Anuh Pharma produces active pharmaceutical ingredients including macrolides, anti-TB drugs, anti-malarial drugs, antibacterial drugs, anti-hypertension drugs, expectorants, and quinolones . The company also manufactures corticosteroids such as anti-inflammatory and immunosuppressant products . Anuh Pharma has a reactor capacity and serves customers across territories .

Anuh Pharma share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on production volumes, raw material costs, capacity utilization rates, export demand, and the performance of its API and corticosteroid segments. Anuh Pharma stock price is influenced by various factors such as earnings, regulatory approvals, changes in drug manufacturing standards, and global generic drug demand trends. In the longer run, strategies such as product portfolio expansion, capacity enhancement, and entry into new therapeutic categories affect the stock market sentiments. All these factors need to be monitored closely to have an idea about Anuh Pharma stock price movements.

Anuh Pharma live share price provides real-time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Anuh Pharma live price helps in observing short term price volatility and shows how a stock moves relative to the broader healthcare index. Furthermore, monitoring Anuh Pharma stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook.

Anuh Pharma Fundamentals

A. Company Background

Anuh Pharma Limited is an Indian pharmaceutical company incorporated in 1989. It is headquartered in Mumbai, Maharashtra, India. The company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), primarily focusing on bulk drugs used in formulations for therapeutic applications. Its product portfolio includes antibiotics and other pharmaceutical intermediates. The company operates a manufacturing facility located in Tarapur, Maharashtra, and supplies its products to both domestic and international markets. Over time, it has built capabilities in regulated markets through compliance with international quality standards such as GMP certifications. Its business model is primarily B2B, supplying APIs to pharmaceutical formulation companies globally.

B. Company Product Lines

• Macrolide Antibiotics: APIs such as Erythromycin used in anti-infective formulations.

• Anti-Infective APIs: Pharmaceutical ingredients used in treating bacterial infections.

• Anti-Tuberculosis (Anti-TB) APIs: Active ingredients used in tuberculosis treatment formulations.

• Other Bulk Drug Intermediates: Chemical compounds used in pharmaceutical manufacturing processes.

The company operates as a bulk drug manufacturer supplying APIs to pharmaceutical formulation companies for further processing into finished medicines.

C. Company Revenue Model

• API Sales: Primary revenue from sale of active pharmaceutical ingredients to pharmaceutical companies.

• Export Sales: Revenue generated from international customers across regulated and semi-regulated markets.

• Domestic Sales: Supply of APIs to Indian pharmaceutical manufacturers.

• Contract-Based Supply: Long-term and recurring supply arrangements with formulation companies.

Revenue is influenced by demand cycles in the pharmaceutical industry, raw material costs, and regulatory compliance requirements in export markets.

D. Geographic Presence

• Corporate Headquarters: Mumbai, Maharashtra, India.

• Manufacturing Facility: Tarapur, Maharashtra, India.

• Domestic Market: Supplies APIs to pharmaceutical companies across India.

• Export Markets: Products supplied to international markets including Europe, Africa, and other regulated and semi-regulated regions.

The company operates primarily from a single manufacturing base with a strong export-oriented distribution model.

E. Key Milestones

• 1989: Incorporation of the company for manufacturing bulk drugs.

• 2000s: Expansion into regulated export markets through quality certifications and compliance improvements.

• 2010s: Strengthening of API product portfolio including anti-infective and anti-TB segments.

• Recent years: Continued focus on export-driven growth and compliance with international pharmaceutical standards.

F. Industry Perspective

The active pharmaceutical ingredient (API) industry in India is a key part of the global pharmaceutical supply chain, supplying raw materials for finished drug manufacturing. Demand is driven by global healthcare consumption, increasing pharmaceutical outsourcing, and growing requirements for cost-effective drug production. The industry is highly regulated, requiring compliance with international quality standards and periodic audits. At the same time, companies face volatility in raw material prices and dependency on China for certain chemical intermediates. Export competitiveness is influenced by regulatory approvals, production efficiency, and pricing pressures. Overall, the sector benefits from long-term structural demand for medicines, but profitability is cyclical due to input cost fluctuations and regulatory compliance requirements.

Anuh Pharma Limited Stock Market Presence: Listings & Index Representation

Anuh Pharma Limited is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) . Anuh Pharma share price is available for trading on the NSE under the symbol ANUHPHR and on the BSE with the scrip code 506260 . The company’s market presence is primarily within the small-cap segment of the market, classified under BSE Group B and the BSE SmallCap index . Due to its size and sector focus, Anuh Pharma stock price is generally tracked by investors interested in the pharmaceutical and healthcare industry.

Anuh Pharma Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India . While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the BSE SmallCap, BSE Healthcare, and S&P BSE AllCap indices . Anuh Pharma share price finds representation in these indices based on its market standing. This presence helps investors track the stock relative to other pharmaceutical and healthcare companies.

Anuh Pharma Limited Stock Performance and Share Price History

Anuh Pharma share price on NSE reflects its status as a bulk drug and API manufacturer in India. Performance is driven by production capacity utilization, raw material cost management, export sales growth, and the company’s ability to manage operational expenses. Investors compare Anuh Pharma share price today with other pharmaceutical manufacturers and API producers to gauge relative performance .

These underlying factors are often visible through real market movements across different periods. Similar trends are observed during earnings-driven movements. Broader sector strength has also played a role in supporting Anuh Pharma share price. In addition to operational and sector-led factors, the company’s consistent dividend payments can also have a significant impact on Anuh Pharma share price movements short-term even when a company’s fundamentals remain strong. The company has paid dividends in recent years, showing its ability to reward shareholders. This shows how corporate actions can trigger short-term swings, even within a regulated pharmaceutical framework influenced by drug pricing policies and regulatory compliance.

While short-term movements reflect events and announcements, longer-term valuation trends are visible through Anuh Pharma share price 52-week high and low, providing context beyond daily or weekly changes . Based on available data, the stock’s 52-week high and low indicate a wide trading range over the past year . Highs suggest strong API demand and stable margins, while lows align with market corrections or sector volatility. These levels capture impacts of pharmaceutical policies, global generic drug trends, and earnings visibility, providing context for the stock’s historical performance.

Anuh Pharma’s stock performance reflects the trading behaviour of a small-cap pharmaceutical company operating within India’s drug manufacturing ecosystem. The company’s focused portfolio across macrolides, anti-TB drugs, and corticosteroids has shaped its Anuh Pharma share price history. Over the past decade, the stock has shown periods of sharp gains and phases of consolidation. The stock recorded a positive one-year return of 86.8% over three years, while delivering a negative one-year return of 1.9% . From recent periods onwards, the Anuh Pharma share price has shown corrective momentum following the previous sharp upmove.

Anuh Pharma’s stock performance over time has closely followed India’s pharmaceutical demand and global generic drug cycles. The Anuh Pharma share price showed positive momentum when demand for macrolide antibiotics and corticosteroids increased during the pandemic period . However, periods of high raw material costs and competitive pressures have contributed to consolidation in Anuh Pharma stock price. Over longer investment horizons, the stock has shown positive five-year returns of 45.9% and an exceptional return since its IPO of 788.9% . These returns highlight consistent growth aligned with expanding pharmaceutical manufacturing across the Indian economy.

Despite COVID-19 disruptions, Anuh Pharma shares showed resilience during the pandemic period. While the broader pharmaceutical sector faced challenges with supply chain disruptions and logistics, the company’s focus on essential antibiotic and corticosteroid products helped the stock retain value. Prudent management across its manufacturing operations kept shares stable amid the pandemic’s challenges and market volatility.

Anuh Pharma share price has seen decreases due to several recurring reasons. A decline in export demand or a drop in API realizations directly impacts profitability and leads to selling pressure. Changes in government policy, such as stricter environmental regulations for pharmaceutical manufacturing or changes in drug price controls, can also cause the stock to fall. Furthermore, any increase in operational costs like raw material procurement or energy expenses without a matching rise in product prices squeezes the company’s margins, making the stock less attractive. Periods of global economic slowdown that affect pharmaceutical spending raise concerns about export volumes, leading to a drop in Anuh Pharma share price. Broader market sell-offs in small-cap stocks also pull the price down, regardless of the company’s individual performance. A decrease in capacity utilization or lower sales in any product category directly hurts the company’s revenue, resulting in a lower valuation for Anuh Pharma share price. The stock has also faced headwinds from intense competition in the API segment and pricing pressures from generic drug manufacturers.

Anuh Pharma Limited Investor Relevance and Role in Portfolio

Anuh Pharma Limited is a holding in small-cap and pharmaceutical portfolios, offering exposure to API manufacturing, macrolide antibiotics, and corticosteroids. Inclusion in healthcare indices underscores its importance in India’s bulk drug manufacturing space. The company’s diversified product portfolio, established manufacturing facilities, and long operating history make it a consideration for long-term allocations .

Anuh Pharma share price is influenced by the company’s ownership structure. Anuh Pharma equity is held by a broad mix of promoters and public investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake of approximately 71.8% in the company, reflecting strong internal control . Foreign institutional investors hold a negligible portion of the company’s shares, while domestic institutional investors hold no stake . The public holds the remaining stake of approximately 28.2% in the company . Among mutual fund holders, Bandhan BSE Healthcare Index Fund and Motilal Oswal BSE Healthcare ETF hold small positions in the company . This investor base with stable promoter participation underscores the company’s role as a holding in both domestic and focused portfolios concentrating on pharmaceutical manufacturing.

Beyond fundamentals and ownership, Anuh Pharma stock is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on production levels, export orders, and regulatory policy actions. The stock is available for trading on both the NSE and BSE, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements.

Technical indicators provide additional insight into short-term momentum shifts in the company’s stock price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short-term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends.

Based on available data, Anuh Pharma share price beta varies across different timeframes . The long-term beta stands at 0.34, indicating that the stock generally shows lower volatility compared to the broader market over an extended period . On a daily basis, the beta values reflect specific levels of correlation with market movements, with a beta of 0.85 reported in some sources . Over medium-term cycles, the beta suggests relatively stable fluctuations. The stock’s average weekly movement of 5.1% has been slightly lower than the pharmaceutical industry average of 5.4% and the market average of 5.8% . Overall, Anuh Pharma demonstrates a lower volatility profile compared to the broader market, with the stock generally considered to have below-average systematic risk, making it a relatively defensive holding within the pharmaceutical sector.

Anuh Pharma Limited Sectoral Relevance and Peer Positioning

Anuh Pharma Limited sector relevance stems from its scale in bulk drug manufacturing across India, its portfolio of macrolides, anti-TB drugs, anti-malarial drugs, and corticosteroids, and its established customer base in domestic and international markets, establishing it as a focused small-cap pharmaceutical provider supporting India’s API manufacturing ecosystem . Peer comparisons with companies like Sun Pharma, Divi’s Laboratories, Torrent Pharma, Cipla, and other pharmaceutical manufacturers focus on production capacity, product mix, regulatory compliance, and geographical presence rather than short-term stock moves . These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of API demand, generic drug trends, and regulatory compliance further highlights Anuh Pharma positioning within India’s broader pharmaceutical manufacturing market.

Anuh Pharma P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from API and corticosteroid sales. In earlier years, the ratio remained at certain levels, indicating measured market expectations . Around recent periods, following earnings performance, the valuation changed as investors reassessed the company’s future prospects. The current P/E ratio stands at a level that reflects the company’s earnings potential in a competitive generic drug market . Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a cyclical industry.

Alongside valuation, Anuh Pharma EPS provides insight into its operational performance and income generation from macrolide antibiotics, anti-TB drugs, anti-malarial drugs, anti-hypertension products, and corticosteroid formulations . Between earlier fiscal years, earnings per share reflected periods of growth followed by moderation. The company reported an EPS of 4.17 in recent periods . In recent periods, EPS changed due to the impact of varying production margins and raw material costs. The company has reported consistent profitability in different years, though margins have shown some variation based on operating costs .

Anuh Pharma market cap highlights its position as a small-cap player within India’s pharmaceutical sector . Based on recent data, the company continues to hold a specific position due to its API manufacturing capabilities and established customer base across multiple therapeutic categories. This manufacturing specialization strengthens its visibility among focused investors and supports consistent investment interest, reinforcing its role as a key bulk drug provider. Finally, Anuh Pharma earnings trajectory demonstrates the impact of its operational execution in a competitive industry. In recent fiscal years, total income showed trends supported by the core API business . The company’s revenue has shown growth in certain years followed by moderation, while net profit has also shown variation reflecting market conditions . The company reported revenue growth of 2.24% in the latest fiscal year with a net profit margin of 7.16% . These developments illustrate the company’s position as a focused pharmaceutical manufacturer with a clear business model centered on API and corticosteroid production.

Summary

Anuh Pharma Limited operates as a bulk drug and API manufacturer serving domestic and international pharmaceutical markets. Anuh Pharma share price moves largely with generic drug demand cycles, raw material costs, and broader pharmaceutical sector conditions. Anuh Pharma stock price reflects its specific position within the small-cap API manufacturing space. The company’s performance aligns with the operational results of its focused product portfolio and capacity utilization rates.